1
|
Ma H, Liu J, Wu W, He P. Interleukin-1α, Interleukin-1β and Interleukin-1 Receptor Antagonist Share a Common U-shaped Recognition Epitope on Interleukin-1 Receptor Surface. J Mol Recognit 2022; 35:e2963. [PMID: 35561040 DOI: 10.1002/jmr.2963] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 04/28/2022] [Accepted: 05/11/2022] [Indexed: 11/06/2022]
Abstract
Interleukin-1 (IL-1) plays a central role in the regulation of immune and inflammatory responses. There are two forms of IL-1 agonists (IL-1α and IL-1β) and one form of IL-1 antagonist (IL-1Ra); they share a similar binding mode to IL-1 receptor (IL-1R) but exhibit opposite biological functions on the receptor. In this study, the intermolecular interactions of IL-1R receptor with IL-1α, IL-1β and IL-1Ra ligands were systematically investigated at structural, energetic and dynamic levels. It was found that the receptor primarily adopts a U-shaped, double-stranded and linear/conformational-hybrid epitope to commonly interact with the three ligands. The epitope covers a common protein segment (residues 107-127), which is fully located within in the C2T2 subsdomain of IL-1R extracellular domain (ECD) and contributes ~40% to the total binding energy of IL-1R/ligand association. The epitope is natively folded into an ordered conformation in IL-1R protein context but would become largely disordered out of the context. Here, we adopted a disulfide bridge to staple U-shaped epitope-derived peptides, which can be effectively constrained into a native-like conformation and thus exhibit an improved affinity to ligands as compared to their unstapled counterpart, with affinity increase by up to ~15-fold. These disulfide bridges were designed to point out of ligand/peptide complex interface and thus would not disrupt the direct complex interaction. Energetic decomposition imparted that the stapling has only a modest influence on the interaction enthalpy and desolvation effect of ligand/peptide binding, but can substantially reduce entropy penalty upon the binding. For a peptide, the stapling-addressed entropic reduction can be roughly regarded as a constant, which only improves peptide affinity to these ligands, but does not change peptide selectivity over different ligands. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Huaijun Ma
- Department of Cardiac Surgery, Southwest Hospital, Army Medical University, Chongqing, China.,Department of Surgery, Guangyuan Hospital of Traditional Chinese Medicine, Guangyuan, China
| | - Jie Liu
- Department of Thoracic Surgery, Southwest Hospital, Army Medical University, Chongqing, China
| | - Wei Wu
- Department of Thoracic Surgery, Southwest Hospital, Army Medical University, Chongqing, China
| | - Ping He
- Department of Cardiac Surgery, Southwest Hospital, Army Medical University, Chongqing, China
| |
Collapse
|
2
|
Pyrillou K, Burzynski LC, Clarke MCH. Alternative Pathways of IL-1 Activation, and Its Role in Health and Disease. Front Immunol 2020; 11:613170. [PMID: 33391283 PMCID: PMC7775495 DOI: 10.3389/fimmu.2020.613170] [Citation(s) in RCA: 73] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Accepted: 11/16/2020] [Indexed: 02/06/2023] Open
Abstract
Cytokines activate or inhibit immune cell behavior and are thus integral to all immune responses. IL-1α and IL-1β are powerful apical cytokines that instigate multiple downstream processes to affect both innate and adaptive immunity. Multiple studies show that IL-1β is typically activated in macrophages after inflammasome sensing of infection or danger, leading to caspase-1 processing of IL-1β and its release. However, many alternative mechanisms activate IL-1α and IL-1β in atypical cell types, and IL-1 function is also important for homeostatic processes that maintain a physiological state. This review focuses on the less studied, yet arguably more interesting biology of IL-1. We detail the production by, and effects of IL-1 on specific innate and adaptive immune cells, report how IL-1 is required for barrier function at multiple sites, and discuss how perturbation of IL-1 pathways can drive disease. Thus, although IL-1 is primarily studied for driving inflammation after release from macrophages, it is clear that it has a multifaceted role that extends far beyond this, with various unconventional effects of IL-1 vital for health. However, much is still unknown, and a detailed understanding of cell-type and context-dependent actions of IL-1 is required to truly understand this enigmatic cytokine, and safely deploy therapeutics for the betterment of human health.
Collapse
Affiliation(s)
| | | | - Murray C. H. Clarke
- Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom
| |
Collapse
|
3
|
De Masson A, Giustiniani J, Marie-Cardine A, Bouaziz JD, Dulphy N, Gossot D, Validire P, Tazi A, Garbar C, Bagot M, Merrouche Y, Bensussan A. Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes. Oncoimmunology 2016; 5:e1127493. [PMID: 27467939 DOI: 10.1080/2162402x.2015.1127493] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Revised: 11/25/2015] [Accepted: 11/25/2015] [Indexed: 12/31/2022] Open
Abstract
CD245 is a human surface antigen expressed on peripheral blood lymphocytes, initially delineated by two monoclonal antibodies DY12 and DY35. Until now, CD245 molecular and functional characteristics remained largely unknown. We combined immunological and proteomic approaches and identified CD245 as the unconventional myosin 18A, a highly conserved motor enzyme reported as a receptor for the surfactant protein A (SP-A), that plays a critical role in cytoskeleton organization and Golgi budding. We report that the recruitment of CD245 strongly enhanced NK cell cytotoxicity. Further, we show that the enhancement of the NK lymphocytes killing ability toward CD137-ligand expressing target cells could result from the induction of CD137 expression following CD245 engagement. The SP-A receptor could therefore represent a novel and promising target in cancer immunotherapy.
Collapse
Affiliation(s)
- A De Masson
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche Scientifique (UMRS)-976, Laboratoire "Oncodermatology, Immunology and Cutaneous Stem Cells", Hôpital Saint-Louis, Paris, France; Université Paris VII Paris Diderot, Sorbonne Paris Cité, Paris, France; Service de Dermatologie, Hôpital Saint-Louis, Paris, France; Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - J Giustiniani
- Institut Jean Godinot, Unicancer, Reims, France; Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51 rue Cognacq-Jay , Reims cedex, France
| | - A Marie-Cardine
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche Scientifique (UMRS)-976, Laboratoire "Oncodermatology, Immunology and Cutaneous Stem Cells", Hôpital Saint-Louis, Paris, France; Université Paris VII Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - J D Bouaziz
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche Scientifique (UMRS)-976, Laboratoire "Oncodermatology, Immunology and Cutaneous Stem Cells", Hôpital Saint-Louis, Paris, France; Université Paris VII Paris Diderot, Sorbonne Paris Cité, Paris, France; Service de Dermatologie, Hôpital Saint-Louis, Paris, France
| | - N Dulphy
- Université Paris VII Paris Diderot, Sorbonne Paris Cité, Paris, France; INSERM UMRS-1160, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France; Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - D Gossot
- Service de chirurgie thoracique, Institut Mutualiste Montsouris , Paris, France
| | - P Validire
- Service d'anatomopathologie, Institut Mutualiste Montsouris , Paris, France
| | - A Tazi
- Université Paris VII Paris Diderot, Sorbonne Paris Cité, Paris, France; Service de pneumologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - C Garbar
- Institut Jean Godinot, Unicancer, Reims, France; Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51 rue Cognacq-Jay , Reims cedex, France
| | - M Bagot
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche Scientifique (UMRS)-976, Laboratoire "Oncodermatology, Immunology and Cutaneous Stem Cells", Hôpital Saint-Louis, Paris, France; Université Paris VII Paris Diderot, Sorbonne Paris Cité, Paris, France; Service de Dermatologie, Hôpital Saint-Louis, Paris, France
| | - Y Merrouche
- Institut Jean Godinot, Unicancer, Reims, France; Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51 rue Cognacq-Jay , Reims cedex, France
| | - A Bensussan
- Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche Scientifique (UMRS)-976, Laboratoire "Oncodermatology, Immunology and Cutaneous Stem Cells", Hôpital Saint-Louis, Paris, France; Université Paris VII Paris Diderot, Sorbonne Paris Cité, Paris, France
| |
Collapse
|